News
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
About 7 million people enrolled in Medicare and Medicaid would gain access to weight-loss drugs like Ozempic, Wegovy, Zepbound and Mounjaro, which are not covered by these federal programs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results